HemoSonics

OverviewSuggest Edit

HemoSonics, LLC is a privately held medical device company founded to develop and bring to market innovative in vitro diagnostics to characterize hemostasis in a variety of clinical settings. These systems employ a patented approach named sonorheometry (SR), which is faster, easier to use, and has a lower cost than competing technologies. Our products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy. This approach makes our system easier to operate and interpret than existing products. Potential clinical applications include trauma, cardiovascular procedures, organ transplantation, orthopedic surgery, neurological surgery, and labor and delivery among others. Sonorheometry was invented by company founders Walker, Viola, and Lawrence while at the University of Virginia. This technology has undergone clinical and laboratory testing supported by a series of academic and business grants from the National Institutes of Health, the Wallace H. Coulter Foundation for Translational Research, the Office of Naval Research, and private investors. Sonorheometry has been demonstrated in a series of peer-reviewed scientific publications and has undergone both laboratory and clinical evaluation. Standalone prototypes are undergoing further clinical and laboratory evaluation. 
TypePrivate
Founded2004
HQCharlottesville, VA, US
Websitehemosonics.com
Overall CultureA+

Latest Updates

Employees (est.) (Jun 2021)84(+2%)
Cybersecurity ratingAMore

Key People/Management at HemoSonics

Bob Roda

Bob Roda

President and Chief Executive Officer
Deborah Winegar

Deborah Winegar

Vice President, Clinical Affairs
Francesco Viola

Francesco Viola

Founder and Chief Scientific Officer
Raymond L Szafranski

Raymond L Szafranski

Chief Financial Officer
David Bryant

David Bryant

Vice President, Operations
Lee DeGeer

Lee DeGeer

Chief Commercial Officer
Show more

HemoSonics Office Locations

HemoSonics has offices in Charlottesville and Asnières-sur-Seine
Charlottesville, VA, US (HQ)
400 Preston Ave
Charlottesville, VA, US
400 Preston Ave #250
Asnières-sur-Seine, FR
3 Allée Theresa
Show all (3)

HemoSonics Financials and Metrics

Summary Metrics

Founding Date

2004

HemoSonics total Funding

$17.3 m

HemoSonics latest funding size

$15 m

Time since last funding

4 years ago
HemoSonics's latest funding round in February 2017 was reported to be $15 m. In total, HemoSonics has raised $17.3 m
Show all financial metrics

HemoSonics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

HemoSonics Online and Social Media Presence

Embed Graph

HemoSonics Company Culture

  • Overall Culture

    A+

    88/100

  • CEO Rating

    A+

    85/100

  • Compensation

    A+

    100/100

Learn more on Comparably

HemoSonics Blogs

HemoSonics Welcomes FDA Support of Viscoelastic Coagulation Analyzers for COVID-19 Patients; Highlights the Benefits of the Quantra® Hemostasis Analyzer

Charlottesville, VA, January 19, 2021 – HemoSonics welcomes the January 14th guidance of the US Food and Drug Administration (FDA) that broadens the use of viscoelastic coagulation analyzers for hospital patient healthcare settings in response to COVID-19. The FDA guidance is intended, for the durat…

HemoSonics Adds Remote Viewer to its Quantra® QPlus® System, Bringing Rapid Results to Clinicians Anywhere in the Hospital

Charlottesville, VA – September 10, 2020 – HemoSonics announced today that its Quantra Desktop Remote Viewer Software (QDRV) has received a 510(k) clearance from the FDA. The QDRV enables remote access to its flagship product, the Quantra QPlus System. The Quantra System provides rapid, actionable c…

Quality Assurance in Viscoelastic Testing – Reducing the QC Burden with the Quantra® System

In a recent publication entitled Unique Approach to Quality Assurance in Viscoelastic Testing (Leadbetter NH, et al, J Appl Lab Med. 2020 May 20, HemoSonics authors describe a novel POC device, the Quantra QPlus® System, with emphasis on a comprehensive, easy-to-implement QA program. Importantly, th…

COVID-19 Update from HemoSonics

HemoSonics has responded to requests from several clinical sites in Europe and is supporting their investigations to understand the potential utility of the Quantra System for the evaluation of blood coagulation status in COVID-19 patients at the point-of-care. The Quantra Hemostasis Analyzer and it…

SCA 2020 Annual Meeting & Workshops

The 2020 SCA Annual Meeting and Workshops will gather more than 1,200 specialized physicians and trainees in the research and treatment of patients undergoing cardiovascular and thoracic procedures. Visit HemoSonics at SCA-2020 at Booth #401 on April 19-21 in West Palm Beach, FL, and see a live demo…

THSNA 2020

THSNA 2020 -Thrombosis & Hemostasis Summit of North America - is a collaboration of 14 leading non-profit organizations in the fields of Thrombosis and Hemostasis. The Summit provides a focused forum for over 1,500 attendees with an interest in bleeding and clotting disorders to network, learn, …
Show more

HemoSonics Frequently Asked Questions

  • When was HemoSonics founded?

    HemoSonics was founded in 2004.

  • Who are HemoSonics key executives?

    HemoSonics's key executives are Bob Roda, Deborah Winegar and Francesco Viola.

  • How many employees does HemoSonics have?

    HemoSonics has 84 employees.

  • Who are HemoSonics competitors?

    Competitors of HemoSonics include Sysmex, Aspect Imaging and Magnolia Medical Technologies.

  • Where is HemoSonics headquarters?

    HemoSonics headquarters is located at 400 Preston Ave, Charlottesville.

  • Where are HemoSonics offices?

    HemoSonics has offices in Charlottesville and Asnières-sur-Seine.

  • How many offices does HemoSonics have?

    HemoSonics has 3 offices.